Therapeutic Workshop
The New Cancer Agents: Translating Promise into the Clinic
Wednesday, October 19
9:10 a.m. - 10:10 a.m.
Telegraph Hill
Do promising science and preclinical observations translate into clinical opportunity? How do you interpret the early signals, determine the best development pathway and how to allocate resources? How should companies be handling such issues as pharmacodynamic measures of effect, patient enrichment and maximum tolerated versus optimal biological dosing? Panelists discussed approaches to determining most-promising first indication, pursuing mono or combination clinical studies, toxicity and dosing profiles, future endpoints, establishing clear proof of concept, and how to set investor expectations.
Moderator:
- Jim Birchenough, MD, Senior Vice President, Biotechnology Equity Research, Lehman Brothers, Inc.
Panelists:
- Daniel C. Adelman, MD, Senior Vice President, Drug Discovery and Development, Sunesis Pharmaceuticals, Inc.
- Susan Molineaux, PhD, Chief Scientific Officer, Proteolix, Inc.
- James H. Sabry, MD, PhD, President and CEO, Cytokinetics, Inc.
- Edward F. Schnipper, MD, President and CEO, Cellgate, Inc.